Apnimed, Inc.

Healthcare · Biotechnology · United States

Last price 16.4 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 682.74M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.